MedTrace Logo

Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)

NCT00167518 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2005-09-14

No results posted yet for this study

Summary

The trial will test the hypothesis that an intravitreal injection of triamcinolone is safe and efficacious for patients with clinically significant diabetic macular oedema that is recalcitrant to conventional laser therapy

Conditions

  • Diabetic Macular Oedema

Interventions

DRUG

Triamcinolone acetate

Sponsors & Collaborators

  • University of Sydney

    lead OTHER

Principal Investigators

  • Mark C Gillies, MBBS, PhD · Save Sight Institute, Deaprtment of Clinical Ophthalmology, University of Sydney

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Completion
2005-04-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00167518 on ClinicalTrials.gov